Company: NCEL
Filing Date: 2025-09-10
Form Type: 424B3
Source: 0001213900-25-086600
Chunk: 81

Company: NewcelX Ltd.
Filing Date: 2025-09-10
Form: 424B3
Chunk 81
---
 Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com). Shareholders can only cast as many votes at their shareholding at the record date entitle them to. Q.Will the NLS Board and Kadimastem Board obtain a third -party valuation report or fairness opinion in determining whether or not to proceed with the Merger? The Kadimastem Board obtained a fairness opinion and a valuation report relating to the Merger in a form reasonably satisfactory to it. The fairness opinion was not prepared for the benefit of NLS’s shareholders and accordingly, NLS’s shareholders are not entitled to rely on the fairness opinion. Additionally, the fairness opinion does not opine on the fairness of the Exchange Ratio to NLS or NLS’s shareholders. For more information, please see the section entitled “ Fairness Opinions and Valuation Reports of Moore Financial Consulting” in this proxy statement/prospectus. Q.Do I have appraisal rights in connection with the proposed Merger? Holders of NLS Common Shares do not have appraisal rights under the laws of the State of Israel or under the laws of Switzerland in connection with the Merger. Q.Who is paying for this proxy solicitation? NLS will bear the cost of soliciting proxies. In addition to these proxy materials, NLS’s directors and employees may also solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. NLS may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners. Q.What will happen to Kadimastem’s equity awards plans? At the Effective Time each option, restricted share unit, restricted share, warrant or other rights issued and outstanding, whether vested or unvested, to purchase Kadimastem Ordinary Shares, shall be assumed by NLS and converted into an option, warrant, other award, or right, as applicable, to purchase NLS Common Shares in accordance with the terms of the Merger Agreement. Q.What is the anticipated ownership of the combined company following the Merger? The Exchange Ratio will be determined based on a formula that is expected to result in the Initial Split, subject to adjustment pursuant to the terms of the Merger Agreement, including as a result of estimated cash of NLS and Kadimastem and estimated indebtedness of NLS, in each case as of the Measurement Date. Based on various